Research at Boehringer Ingelheim RCV GmbH & Co KG in Vienna - Boehringer Ingelheim's dedicated drug discovery center for new cancer drugs.
Cancer patients, their families, and doctors are painfully aware of the need for more effective, better tolerated drugs. Each year, there are about 12 million new cases diagnosed and seven million cancer deaths worldwide.
We are committed to finding improved cancer medicines through state-of-the-art drug discovery efforts that harness the scientific advances in cancer genetics, biology, and bioinformatics and utilize our expertise in small-molecule drugs as well as biopharmaceuticals.
The driving force in reaching our goals is a talented, highly motivated workforce, drawn from a dozen countries spanning the globe. Our in-house efforts are strengthened by alliances with leading labs in academia and biotech companies; one significant link is our interaction with the corporation’s basic research institute, the Institute of Molecular Pathology, also located in Vienna.